A mitochondrial-targeted ubiquinone modulates muscle lipid profile and improves mitochondrial respiration in obesogenic diet-fed rats

Charles Coudray^{1*}, Gilles Fouret¹, Karen Lambert², Carla Ferreri³, Jennifer Rieusset⁴, Agnieszka Blachnio-Zabielska⁵, Jérôme Lecomte⁶, Raymond Ebabe Elle², Eric Badia², Michael P. Murphy⁷ and Christine Feillet-Coudray¹

¹UMR 866 (Muscular Dynamic & Metabolism), INRA, Place Viala, 34060 Montpellier, France

²U1046 INSERM, UMR9214 CNRS, Université de Montpellier, 34295 Montpellier, France

³Istituto per la Sintesi Organica e la Fotoreattività (ISOF) Bio Free Radicals, 40129 Bologna, Italy

⁴UMR U1060, INSERM/Faculté de médecine Lyon-Sud, 69921 Oullins, France

⁵Department of Physiology, Medical University, Mickiewicza 2c, 15-222 Białystok, Poland

⁶Centre de recherche agronomique pour le développement (CIRAD)/SupAgro, UMR IATE, F-34398 Montpellier, France

⁷Medical Research Council Mitochondrial Biology Unit, Hills Road, Cambridge CB2 0XY, UK

(Submitted 22 July 2015 – Final revision received 10 December 2015 – Accepted 22 December 2015 – First published online 9 February 2016)

Abstract

The prevalence of the metabolic syndrome components including abdominal obesity, dyslipidaemia and insulin resistance is increasing in both developed and developing countries. It is generally accepted that the development of these features is preceded by, or accompanied with, impaired mitochondrial function. The present study was designed to analyse the effects of a mitochondrial-targeted lipophilic ubiquinone (MitoQ) on muscle lipid profile modulation and mitochondrial function in obesogenic diet-fed rats. For this purpose, twenty-four young male Sprague–Dawley rats were divided into three groups and fed one of the following diets: (1) control, (2) high fat (HF) and (3) HF+MitoQ. After 8 weeks, mitochondrial function markers and lipid metabolism/profile modifications in skeletal muscle were measured. The HF diet was effective at inducing the major features of the metabolic syndrome – namely, obesity, hepatic enlargement and glucose intolerance. MitoQ intake prevented the increase in rat body weight, attenuated the increase in adipose tissue and liver weights and partially reversed glucose intolerance. At the muscle level, the HF diet induced moderate TAG accumulation associated with important modifications in the muscle phospholipid classes and in the fatty acid composition of total muscle lipid. These lipid modifications were accompanied with decrease in mitochondrial respiration. MitoQ intake corrected the lipid alterations and restored mitochondrial respiration. These results indicate that MitoQ protected obesogenic diet-fed rats from some features of the metabolic syndrome through its effects on muscle lipid metabolism and mitochondrial activity. These findings suggest that MitoQ is a promising candidate for future human trials in the metabolic syndrome prevention.

Key words: High-fat diet: Metabolic syndrome: Muscle: MitoQ: Mitochondria: Phospholipids: Fatty acids

The metabolic syndrome is a clustering of cardiovascular risk factors, including abdominal obesity, dyslipidaemia, mitochondrial dysfunction and insulin resistance (IR)⁽¹⁾. Its prevalence is high in both developed and developing countries, where obesity and its related problems are increasing rapidly. Increased consumption of energy-dense foods containing high amounts of animal fats, SFA and fructose is thought to be the major contributor to the current epidemic of metabolic disorders⁽²⁾. In addition to the chronic imbalances between energy supply and energy demands, there are many studies confirming that increased availability of SFA in muscle and liver is associated with IR^(3,4). Muscle TAG accumulation could occur because of increased availability and

uptake of systemic free fatty acids (FFA)⁽⁵⁾. Another possibility is that impaired muscle fatty acid oxidation (even in the presence of unaltered uptake) leads to excess cytosolic lipid accumulation^(6,7). The relative contribution of the different sources of excess lipid to muscle is not currently known in quantitative terms, and a combination of both factors (oversupply and impaired oxidation) may be a possibility. Although TAG accumulation is not a problem *per se* and can even be protective, the intracellular accumulation of long-chain CoA or various lipid derivatives is known to be disruptive. Mitochondrial FFA oxidation may influence glucose oxidation via the classic glucose–fatty acid (Randle) cycle⁽⁸⁾. Changes in the level of specific fatty acids could result in

Abbreviations: DAG, diacylglycerol; HFD, high-fat diet; IR, insulin resistance; MitoQ, mitochondrial-targeted lipophilic ubiquinone; PC, phosphatidylcholine; SM, sphingomyelin.

* **Corresponding author:** Dr C. Coudray, fax +33 4 6754 5694, email coudray@supagro.inra.fr

production of other lipid species (e.g. specific diacylglycerols (DAG)) that may alter insulin signalling pathways via protein kinase C activation^(9,10). Ceramides can also be generated from increased lipid availability and are known to be among the most active lipid second messengers to inhibit the insulin signalling pathway⁽¹¹⁾.

Mitochondria are central to energy metabolism, as they are involved in the process of oxidative phosphorylation (OXPHOS), converting the energy stored in nutrients into ATP through the action of the mitochondrial respiratory chain complexes reducing O₂ to water. There is a relationship between IR and diminished mitochondrial function⁽¹²⁾. Therefore, given the central position of mitochondria and their key roles in energy metabolism and in the development of the metabolic syndrome, many therapies designed to prevent mitochondrial dysfunction have been developed^(13–15). Among these mitochondrial-targeted therapies, the antioxidant mitochondrial-targeted lipophilic ubiquinone (MitoQ) is widely used and has shown protection against oxidative damage in a wide range of pathologies^(16,17), but little is known about its role in high-fat diet (HFD)-induced obesity models^(18–20).

This study was designed to determine the impact of MitoQ on obesity, glucose intolerance and IR development in obesogenic diet-fed rats, independent of its antioxidant action. Indeed, it is likely that MitoQ can impact on other important physiological mechanisms, particularly through direct effects on both lipid metabolism and mitochondrial activity. In line with this, it was reported that co-enzyme Q analogues may be considered as anti-adipogenic/anti-obesity factors⁽²¹⁾.

This report focused on the skeletal muscle because it is the principal tissue for postprandial insulin-stimulated glucose disposal, and thus the key regulator of glucose homeostasis. The results suggest that MitoQ protected rats exposed to a HFD from some features of the metabolic syndrome through positive muscle lipid metabolism modulation and improved mitochondrial respiration.

Methods

Chemicals and apparatus

MitoQ was provided by R. A. J. Smith from the University of Otago in New Zealand. Peroxidase from horseradish, 2',7'-dichlorofluorescein, ADP, succinate, malate, glutamate, and oligomycin were purchased from Sigma. Rhodamine 123 was purchased from ICN Biomedical. NADPH was purchased from Calbiochem Merck. All other chemicals used were of the highest grade and obtained from Sigma Aldrich or Prolabo. LS 45 Fluorescence spectrometer (PerkinElmer) was used for fluorescence measurements. The Nicolet Evolution 100 spectrophotometer (Thermo Electron Corporation) was used for absorbance measurements.

Animals and diets

In all, twenty-four 6-week-old male Sprague–Dawley rats, weighing 175–200 g (Charles River) were housed two per cage under conditions of constant temperature (20–22°C), humidity (45–50%) and a standard dark cycle (20.00–08.00 hours). The rats were randomised into three groups of eight animals each

and were fed for 8 weeks one of the following semi-purified diets: (1) control diet with 4% lipid as soyabean oil, (2) HFD and (3) HFD with MitoQ (HF-MitoQ). The control diet contained 20% protein, 66% carbohydrate, 4% fat (soyabean oil) w/w plus cellulose and vitamin and mineral mix. The HFD contained 20% protein, 35% carbohydrate, 35% fat (4% soyabean oil + 31% lard) w/w plus cellulose and vitamin and mineral mix. MitoQ was used at a dose of 860 mg/kg diet in the form of methanesulfonate β -cyclodextrin complex, which corresponded to 375 μ mol of MitoQ/kg diet. Rats were given free access to tap water and food. Body weight and food consumption were determined weekly. Our institution guidelines for the care and use of laboratory animals were observed, and all the experimental procedures were approved by the local ethics committee (reference CEEA-LR-12002). This report is part of a larger study where the effects of other antioxidants (apocynin, allopurinol and *N*-acetyl-cysteine) have been investigated and published elsewhere⁽²²⁾.

Oral glucose tolerance test

The oral glucose tolerance test (OGTT) was performed as previously described⁽²³⁾. In brief, on week 7 of diet intake, after 16 h of fasting, rats received by gavage 2 g glucose/kg body weight. Blood was sampled through the tail vein of conscious rats immediately before the gavage and 20, 40, 60, 90, 120 and 180 min afterward, and the blood glucose level was measured using glucose strips and a commercial glucometer (Accu-Chek Active; Roche Diagnostics). The AUC values were calculated by the trapezium method. The AUC values are expressed as mmol glucose/l per s.

Killing of rats and metabolic biochemical analyses

After 4–5 d of the OGTT, after 16 h of fasting, rats were anaesthetised with pentobarbital (40 mg/kg body weight) (Ceva Santé Animale), and blood samples were collected from the abdominal artery with a heparinised syringe and distributed into heparinised and dry tubes. Blood tubes were centrifuged at 1000 **g** for 10 min at 4°C, and plasma or serum samples were collected and stored at –80°C until analysis. Both gastrocnemius were removed and one of them was used for the extemporaneously isolation of fresh muscle mitochondria. The other gastrocnemius as well as the soleus muscles and the liver and the visceral fat were collected, rinsed and weighed.

Plasma glucose, serum total cholesterol, TAG and NEFA levels were measured by enzymatic techniques (Thermo Electron Corp.). Plasma insulin, leptin, TNF- α and IL-6 levels were quantified using ELISA kits (St Charles). IR was evaluated by the homeostasis model assessment of IR (HOMA-IR) formula: (fasting plasma glucose level (mmol/l) $\times$ fasting plasma insulin level (mIU/l))/22.5⁽²⁴⁾.

Muscle expression of TNF- α and IL-6 cytokines

The muscle mRNA expressions of TNF- α and IL-6 genes were determined by RT-quantitative PCR as previously reported⁽²²⁾. Normalisations were made to *RPS9*. The following primer sequences were used: forward TNF- α – GGC ATG GAT CTC

AAA GAC AAC C; reverse *TNF- α* – CAA ATC GGC TGA CGG TGT G (accession no. NM_012675.3); forward *IL-6* – CTC CGG ACT TGT GAA GTA GGG; reverse *IL-6* – ATG AAG TTT CTC TCC GCA AGA (accession no. NM_012589.1); forward *RPS9* – GAA GCT GGG TTT GTC GCA AA; and reverse *RPS9* – CGG AGC CCA TAC TCT CCA AT (accession no. NM_031108.4). Western blotting analyses for determining muscle *TNF- α* and *IL-6* protein expressions were carried out as previously reported⁽²²⁾. β -Actin was used as reference, and blot intensities were measured using ImageJ software (NIH). Antibodies of *TNF- α* (ab66579) and *IL-6* (ab6672) were from Abcam and β -actin antibody (s-c81178) was from Santa Cruz Biotechnology.

Mitochondrial membrane potential, respiration and reactive oxygen species production

Muscle mitochondria were isolated by the differential centrifugation technique⁽²⁵⁾. The protein content of muscle supernatants and mitochondrial suspensions was determined according to Bradford using bovine serum albumin as the standard⁽²⁶⁾.

Mitochondrial membrane potential was monitored according to the method described by Baracca *et al.*⁽²⁷⁾ using rhodamine as a probe. Mitochondrial potential ($\Delta\psi$) change has been evaluated by measuring rhodamine fluorescence at the following steps: with rhodamine label alone (2 μ M) in MIRO5 buffer plus muscle fresh mitochondria (0.25 mg proteins), plus glutamate–malate–succinate (2.5:5:5 mM), plus ADP (0.5 mM). RH-123 fluorescence was measured at 495 nm (excitation) and 525 nm (emission) under continuous stirring.

Mitochondrial respiration was determined by measuring mitochondrial VO_2 in two 2-ml air-tight thermo-stated chambers of high resolution Oxygraph (Oxygraph^{2k}; Oroboros)⁽²⁵⁾. The chambers were equilibrated with the MIRO5 respiration buffer at 37°C and fresh mitochondria were then added (0.4 mg protein) followed by substrates malate–glutamate–succinate (2.5:5:5 mM, state 4) and ADP 0.5 mM (state 3). Respiratory coefficient ratio was calculated as the state 3:state 4 ratio.

Mitochondrial reactive oxygen species (ROS) production was measured on fresh mitochondria as previously described with minor modifications⁽²⁸⁾. In brief, reaction mixtures (2 ml), containing MIRO5 buffer, dihydrodichlorofluorescein (10 μ M) and peroxidase (2 IU/ml), were incubated with 60 μ g of mitochondrial proteins with or without substrates (malate–glutamate–succinate, 2.5:5:5 mM, respectively) and with or without ADP (0.5 mM). Fluorescence was measured 30 min after reaction initiation at 490/525 nm excitation and emission, respectively.

Measurement of mitochondrial enzyme activities

Citrate synthase (CS) was used as the mitochondrial marker and measured in the muscle supernatants according to Srere⁽²⁹⁾. The activities of the four mitochondrial respiratory complexes (complex I, complex II, complex II+III and complex IV) were determined spectrophotometrically⁽²³⁾. ATPase activity (complex V) was determined as described by Teodoro *et al.*⁽³⁰⁾ with minor modifications⁽²³⁾. Moreover, enzymatic activity of mitochondrial medium-chain acyl-CoA dehydrogenase (MCAD)

and β -hydroxyacyl-CoA dehydrogenase (β -HAD) was determined spectrophotometrically^(31,32). Mitochondrial aconitase, reported as a good marker of oxidative stress in oxidative pathologies, was determined on muscle supernatants⁽³³⁾.

Mitochondrial oxidative phosphorylation subunits

The OXPHOS Western blotting kit (MitoSciences) containing a cocktail of monoclonal antibodies was used to semi-quantify the relative levels of the subunits of the mitochondrial OXPHOS complexes: NDUFB8 20 kDa of complex I, Fe-S 30 kDa of complex II, core 2–47 kDa of complex III and α 53 kDa subunit of ATP synthase⁽³⁴⁾. For detection of OXPHOS subunits, all Western blot steps were followed.

Muscle lipid analysis

Muscle samples were homogenised in NaCl (9 g/l) and Triton X-100 (0.1 %), and levels of FFA, TAG and total cholesterol were quantified on the muscle homogenate by enzymatic methods (Wako NEFA-C kit; Oxoid; Cholesterol RTU kit and triglycerides PAP kit; Biomérieux).

Muscle ceramide content and enzymes of ceramide metabolism

The muscle content of ceramide species (C14:0, C16:0, C18:0, C18:1, C20:0, C24:0, C24:1) was determined by means of ultra-HPLC according to Blachnio-Zabielska *et al.*⁽³⁵⁾. The activities of the key enzymes implicated in ceramide metabolism – serine palmitoyltransferase (SPT) and neutral sphingomyelinases (nSMase) and acidic sphingomyelinases), enzymes responsible for ceramide generation, and neutral ceramidase (nCDase) and acidic ceramidase, enzymes responsible for ceramides degradation – were measured using radiolabelled substrates with liquid scintillation counter as previously described⁽³⁶⁾.

Muscle diacylglycerol content in muscle lipid extracts by TLC-densitometry

Muscle lipids were extracted using a mixture of chloroform–methanol (2:1, v/v) in the presence of butylated hydroxytoluene (50 mg/l). The application of lipid extracts of muscle homogenate on silica gel 60 HPTLC plates (250 μ m, 20 $\times$ 10 cm; Merck), pre-treated with 1.5 % p/v boric acid in ethanol (100 %), was automatically performed on a 4-mm band width using a CAMAG ATS4 apparatus. Two developments were performed, first with pentane–chloroform–methanol (52:45:3, by volume) on 60-mm migration distance and second with pentane–diethyl ether (97:3 by volume) on 67-mm migration distance, which allowed the separation of neutral lipids. The scanning of the plates was carried out using a CAMAG TLC scanner 3 operating in the reflectance mode. The plates were scanned at 550 nm after dipping in a solution of copper sulphate 640 mM in H_3PO_4 1.18 M and heating for 20 min at 180°C. The 1-monoacylglycerol (MAG), 1,2-DAG and 1,3-DAG contents were finally identified by comparing their retention factor (R_f) with authentic standards and were quantified using calibration curves of the same standards.

Table 1. Effects of diets on diet consumption, rat body evolution and tissue weights* (Mean values and standard deviations; *n* 6–8 observations)

	Control		HF		HF + MitoQ	
	Mean	SD	Mean	SD	Mean	SD
Initial weight	197	6	197	5	197	6
Final weight	581 ^a	32	632 ^b	36	597 ^{a,b}	45
Diet intake (g/rat per d)	26.9 ^a	1.0	20.6 ^b	0.9	18.4 ^c	1.0
Energy intake (kJ/rat per d)	406	17	464	21	418	21
Energy intake (kcal/rat per d)	97 ^a	4	111 ^b	5	100 ^a	5
Liver (g)	14.0 ^a	1.0	17.1 ^b	2.0	15.4 ^{a,b}	2.3
Adipose tissue (g)	54.1 ^a	9.6	78.4 ^b	15.7	65.7 ^{a,b}	10.3
Gastrocnemius (g)	6.52	0.34	6.33	0.39	6.29	0.46

HF, high fat.

^{a,b,c}Mean values with unlike superscript letters in the same row were significantly different. The limit of statistical significance was set at $P < 0.05$.

* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and liver, muscles and adipose tissues were sampled, rinsed with physiological solution, weighed and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data checked by the Kolmogorov–Smirnov test.

Phospholipid classes in muscle lipid extracts by TLC-densitometry

Muscle lipids were extracted using a mixture of chloroform–methanol (2:1, v/v) in the presence of butylated hydroxytoluene (50 mg/l). P was quantified to determine total muscle phospholipids⁽³⁷⁾. The application of muscle chloroform–methanol extracts on silica gel 60 HPTLC plates (250 µm, 20 × 10 cm), pre-treated with 2.3% p/v boric acid in ethanol (100%), was automatically performed on a 4-mm band width using a CAMAG ATS4 apparatus. The development was performed with methanol–acetic acid–pentane–chloroform (15:10:30:45, by volume), which allowed the separation of phospholipids and neutral lipids on a 60-mm total migration distance. The scanning of the plates was carried out using a CAMAG TLC scanner 3, operating in the reflectance mode. The plates were scanned at 715 nm after dipping in a solution of Blue Spray (1:2:3, v/v/v, Blue Spray–H₂SO₄ 4:2 M–acetone) and heating for 3 min at 55°C. The different classes of phospholipids (phosphatidylcholine (PC); phosphatidylethanolamine (PE); phosphatidylinositol (PI); phosphatidylserine (PS); sphingomyelin (SM); lysophosphatidylcholine (LPC); phosphatidylglycerol (PG); phosphatidic acid (PA) and cardiolipin (CL)) were finally identified by comparing their *R_f* with authentic standards and were quantified using calibration curves of the same standards⁽³⁸⁾.

Fatty acid composition of muscle and muscle phospholipids

Determination of fatty acid composition of the total muscle lipids was carried out using the muscle chloroform–methanol extracts. To determine the fatty acid composition of the muscle phospholipids, the phospholipid fraction was separated from other muscle neutral lipids on TLC plates with hexane–diethyl ether–glacial acetic acid mixture (70:30:1, v/v/v). Plates were dried and sprayed with dichlorofluorescein. Bands corresponding to phospholipids were identified under UV and collected by scraping the silica into a glass tube for further analysis. The dried muscle chloroform–methanol extract and the scraped phospholipid bands were *trans*-esterified with an alkali mixture of KOH–methanol for 10 min at room temperature. The total

Fig. 1. Body weight gain in rats fed either (1) control (cont, ◆), (2) high fat (HF, ■) or (3) HF + MitoQ (▲) diets for 8 weeks. Values are means (*n* 7–8 observations), and standard deviations. Statistical significance among groups was detected as described in the statistical analysis section. The limit of statistical significance was set at $P < 0.05$. In all, twenty-four 6-week-old male Sprague–Dawley rats, weighing 175–200 g, were randomised into three groups of eight animals each and fed their corresponding diets for 8 weeks. Rats were given free access to tap water and food, and body weight and food consumption were determined weekly. MitoQ, mitochondrial-targeted lipophilic ubiquinone; HF + MitoQ, HF with MitoQ.

fatty acid methyl ester pattern was analysed by GC (Agilent Technologies) equipped with a DB-23 column and a flame ionisation detector. Chromatograms were collected, and peaks were integrated and identified by comparison with commercially available references.

Statistical analysis

The sample size was calculated from the expected difference in the AUC of the OGTT between the control group and the HFD group. We expected an AUC about 1.20 times greater in the HF group than in the control group. A standard deviation of 15% of the higher value could be allowed. For a type 1 risk α of 0.05 and power ($1-\beta$) of 80%, the sample size required was eight per group.

Data are expressed as mean values and standard deviations. Normal distribution of data was checked by the Kolmogorov–Smirnov test. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data. Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn's *post hoc* analysis and marked with †. The limit of statistical significance was set at $P < 0.05$. Statistical analyses were performed using the StatView program (SAS Institute).

Results

Mitochondrial-targeted lipophilic ubiquinone intake prevented weight gain, glucose intolerance and muscle lipid accumulation

Although the dietary intake (g/d) was decreased, the energy intake was significantly increased in the HF group but not in the MitoQ group (Table 1). Therefore, the final rat body weight was significantly increased in the HF group compared with the control group, whereas MitoQ intake prevented weight gain (Fig. 1). Moreover, the weight of both liver and adipose tissue was increased in the HF groups, but this increase was largely attenuated

by MitoQ intake. However, the weight of both gastrocnemius and soleus muscles remained unchanged among the studied groups (Table 1).

Two major inflammation markers, TNF- α and IL-6, were determined in this study. Plasma TNF- α was increased significantly in the HF group and increased non-significantly in the HF-MitoQ group compared with the control group. However, plasma IL-6 remained unchanged in all the three experimental groups. In addition, the gene and protein expressions of both TNF- α and IL-6 remained unchanged at the muscle level (Table 2). Although the fasted plasma glucose level remained unchanged among the studied groups, the AUC of the OGTT was increased in the HF group, whereas MitoQ intake attenuated it compared with the control group (Fig. 2). In addition, both plasma insulin level and the HOMA-IR index were decreased by MitoQ intake *v.* both control and HF groups, whereas plasma leptin was increased in both HF and HF-MitoQ groups *v.* the control group (Table 2). Surprisingly, some serum lipid parameters (TAG, NEFA and total cholesterol) were decreased significantly in the HF rat group and MitoQ intake further lowered these parameters. The muscle TAG level was statistically significantly increased (+23%) in the HF group *v.* the control group, whereas MitoQ intake completely prevented this muscle lipid accumulation (Table 2).

Mitochondrial-targeted lipophilic ubiquinone intake restored mitochondrial respiration

The mitochondrial membrane potential and the mitochondrial ROS production measured *ex vivo* were not affected by the HFD or MitoQ intake (Table 3). However, mitochondrial respiration decreased significantly with the HF diet *v.* control diet in the three

Table 2. Effects of diets on blood and muscle lipid, inflammation and insulin-resistance parameters* (Mean values and standard deviations; n 6–8 observations)

	Control		HF		HF + MitoQ	
	Mean	SD	Mean	SD	Mean	SD
Blood parameters						
Plasma glucose (mm)	8.15	1.28	7.70	0.86	8.40	0.95
Plasma insulin (μ g/l)†	6.18a	1.94	6.44a	1.56	3.85b	1.89
HOMA-IR index	61.0a	19.0	61.4a	14.6	35.5b	18.6
Plasma leptin (μ g/l)	4.25a	1.33	8.86b	3.16	6.48a,b	3.14
Plasma TNF- α (ng/l)	7.4a	4.4	15.4b	7.9	12.7a,b	5.6
Plasma IL-6 (ng/l)	116	14	123	20	116	22
Serum TAG (mm)	1.44	0.41	1.04	0.31	0.94	0.25
Serum FFA (μ m)	596a	106	443b	84	411b	61
Serum total cholesterol (mm)	2.01a	0.29	1.55b	0.12	1.76a,b	0.21
Serum HDL-cholesterol (mm)	1.34	0.22	1.12	0.18	1.17	0.09
Muscle parameters						
TAG (μ mol/g ww)†	6.46a	1.42	7.93b	1.25	5.56a	1.00
FFA (μ mol/g ww)	2.28	0.37	2.32	0.23	2.17	0.29
Cholesterol (μ mol/g ww)	1.44	0.17	1.36	0.22	1.37	0.22
TNF- α gene expression	1.00	1.12	1.24	1.29	1.66	1.36
TNF- α protein expression	1.00	0.18	1.01	0.11	1.04	0.26
IL-6 gene expression	1.00	0.50	1.82	1.37	1.97	1.54
IL-6 protein expression	1.00	0.38	1.08	0.32	0.95	0.28

HF, high fat; HOMA-IR, homeostasis model assessment-insulin resistance; ww, wet weight; FFA, free fatty acids.

a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at $P < 0.05$.

* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and blood and muscles were sampled. The muscle was rinsed with physiological solution, weighed and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data checked by the Kolmogorov–Smirnov test.

† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn's *post hoc* analysis.

Fig. 2. Glucose tolerance test in 16-h fasted rats fed either control (cont, ◆), high-fat (HF, ■) or HF+MitoQ (▲) diets for 8 weeks. Values are means (n 7–8 observations), and standard deviations represented by vertical bars. Statistical significance among groups was detected as described in the statistical analysis section. The limit of statistical significance was set at $P < 0.05$. ^{a,b}Group mean values with unlike letters were significantly different. In all, twenty-four 6-week-old male Sprague–Dawley rats, weighing 175–200 g, were randomised into three groups of eight animals each and fed their corresponding diets for 8 weeks. Rats were given free access to tap water and food, and body weight and food consumption were determined weekly. MitoQ, mitochondrial-targeted lipophilic ubiquinone; HF + MitoQ, HF with MitoQ.

studied conditions: mitochondria challenged with glutamate-malate or with glutamate-malate-succinate or with G/M/S plus ADP. MitoQ intake significantly increased mitochondrial respiration back to control values (Fig. 3). However, mitochondrial CS activity, enzymatic activity and the protein expression of mitochondrial chain complexes also remained unchanged in the studied groups (Table 3). Finally, mitochondrial β -oxidation was investigated by assessing the enzymatic activity of two major enzymes (β -HAD and MCAD) in this pathway. The activity of these two enzymes remained unchanged in the studied groups (Table 3).

Mitochondrial-targeted lipophilic ubiquinone intake was without effect on diacylglycerol content, but decreased muscle enzymatic activities of ceramide metabolism

The muscle MAG as well as DAG contents were not significantly affected by either the HF diet or MitoQ intakes (Table 4). However, the HF diet intake trended to increase the muscle

content of both 1,2-DAG (+15%) and 1,3-DAG (+22%), whereas MitoQ tended to decrease both DAG contents back to the control values (–10 and –31 %, respectively).

The total content of muscle ceramides did not change by the HF diet or MitoQ intake. However, some species of ceramides (C14, C16, C18:1, C22 and C24:1) were significantly decreased by HF diet intake while MitoQ administration was without effect. The major ceramide species, the C18, as well as the C20 and C24, remained unchanged in the three studied groups (Table 4).

The activities of the key enzymes implicated in ceramide and SM metabolism showed that SPT activity was decreased non-significantly (–14%) in both HF and HF-MitoQ diets *v.* control diet, whereas the activity of both nCDase and nSMase were increased only in the HF diet *v.* control diet. Interestingly, the MitoQ intake decreased significantly the activity of these two enzymes back to control values (Table 4).

Mitochondrial-targeted lipophilic ubiquinone intake decreased the percentage of sphingomyelin in the muscle

The major finding from the muscle phospholipid analysis was the significant increase in the SM percentage and in the SM:PC ratio with the HF diet compared with the control diet. Interestingly, MitoQ intake was proved to be efficient in normalising SM per cent and SM:PC ratio to control levels (Table 5). The percentage of the other phospholipid classes (LPC, PC, PI, PS, PE, PG, PA and CL) was not altered by either the HF diet or MitoQ intake.

Mitochondrial-targeted lipophilic ubiquinone intake increased muscle PUFA n -3 %

We have analysed the effects of the HF diet and MitoQ intake on the fatty acid composition of total muscle lipids (Table 6). The percentage of total and individual SFA (C16:0 and C18:0) remained unchanged. Apart from this, the HF diet intake was associated with a decrease in 16:1 n -7 and 18:1 n -7 and with an increase in 18:1 n -9% (+100%), and as a consequence a strong tendency for an increase in the level of total MUFA (+45%). The MitoQ intake only slightly decreased the 18:1 n -9% (–20%) and the total MUFA percentage (–18%) in the total muscle lipid compared with the HF diet. The HF diet intake also increased non-significantly the C22:5 n -3% and decreased significantly the C22:6 n -3%, with an overall decrease in the percentage of total PUFA n -3 in the total muscle lipid (Table 6). Interestingly, MitoQ intake increased significantly the total PUFA n -3% (+28%), particularly that of C22:5 n -3 (+19%) and C22:6 n -3 (+25%), compared with the HF diet (Table 6).

Mitochondrial-targeted lipophilic ubiquinone intake decreased the percentage of MUFA in the muscle phospholipids

The HF diet and MitoQ intake were without effect on the percentage of total or individual SFA in muscle phospholipids, although the per cent of C18:0 was non-significantly increased (+15%) with HF diet and MitoQ intake (Table 7).

Table 3. Effects of diets on mitochondrial activity*
(Mean values and standard deviations; *n* 6–8 observations)

	Control		HF		HF + MitoQ	
	Mean	SD	Mean	SD	Mean	SD
Mitochondrial ROS production (pmol H ₂ O ₂ /min per mg protein)						
Mitochondria + G/M/S	636	145	580	147	650	145
Mitochondria + G/M/S + ADP	281	87	289	100	329	118
Mitochondrial membrane potential (arbitrary units/mg protein)						
Mitochondria alone	64.0	5.9	62.9	5.6	65.0	4.3
Mitochondria + G/M/S	76.9	2.9	77.2	2.2	78.3	2.2
Mitochondria + G/M/S + ADP	53.1	5.2	53.1	3.6	54.3	4.5
Enzymatic activity of muscle respiratory chain complexes (mU/mg protein)						
Citrate synthase	630	76	633	70	646	66
Complex I	115	12	119	31	114	18
Complex II	195	25	205	62	198	28
Complexes II + III	31.5	5.0	34.3	6.5	37.6	6.8
Complex IV	179	36	195	52	201	38
Protein expression of muscle respiratory chain complex (WB)						
Complex I	1.00	0.35	0.91	0.34	0.97	0.30
Complex II	1.00	0.46	1.04	0.37	1.06	0.57
Complex III	1.00	0.37	0.98	0.17	1.01	0.32
Complex V	1.00	0.31	1.03	0.22	1.03	0.33
Activity of other mitochondrial enzymes (mU/mg protein)						
MCAD	18.3	2.9	17.8	2.7	19.3	1.6
β-HAD	281	35	303	28	314	37

HF, high fat; ROS, reactive oxygen species; G, glutamate; M, malate; S, succinate; MCAD, medium-chain acyl-CoA dehydrogenase; β-HAD, β-hydroxyacyl-CoA dehydrogenase. The limit of statistical significance was set at *P* < 0.05. There were no significant differences among the three experimental groups for all the stated parameters.

* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data checked by the Kolmogorov–Smirnov test.

On the contrary, the MUFA per cent was highly impacted. The HF diet and MitoQ intake were associated with a significant decrease in the percentages of 16:1 *n*-7 and 18:1 *n*-7, with a strong tendency for a decrease in total MUFA per cent with MitoQ intake (–20%) (Table 7). The HF diet and MitoQ intake did not affect the PUFA *n*-6%, although the per cent of C20:4, *n*-6 was increased non-significantly and significantly with HF diet and MitoQ, respectively. The HF diet intake decreased significantly the PUFA *n*-3%, whereas MitoQ intake slightly prevented this decrease. Indeed, HF diet and MitoQ intake increased the C22:5 *n*-3% and decreased the C22:6 *n*-3% (Table 7).

Discussion

We have investigated the impact of MitoQ, on the development of the metabolic syndrome features in obesogenic diet-fed rats. The results of this study show that the HF diet led to a moderate gain in weight and glucose intolerance associated with slight low-grade inflammation, intramuscular lipid accumulation, membrane phospholipid modification and alteration in muscular mitochondrial respiration. In particular, the HF diet significantly increased the muscle levels of both TAG and SM and significantly decreased the muscle PUFA *n*-3 level. In addition, these HF diet-induced lipid modifications were accompanied with significant decrease in muscle mitochondrial respiration. Interestingly, MitoQ intake prevented body weight gain, improved glucose tolerance, corrected the observed

lipid alterations and restored mitochondrial respiration. These results suggest that muscle lipid modulation and mitochondrial respiration restoration by MitoQ intake may mediate the prophylactic action of MitoQ in some metabolic syndrome features in HFD-fed rats. Although our results show that MitoQ intake was accompanied by slight but significant decrease in food and energy intakes (about –10%) compared with the HF group, the food consumption was rather stable during the whole experimental period, and thus the cause for this food intake decrease did not seem to be due to food aversion. The mechanism involving decreased energy intake with MitoQ may be mediated at the hypothalamic level as reported by Fink *et al.*⁽³⁹⁾ for the effects of quinols in mice fed HFD.

Low-grade inflammation is a characteristic of the obese state, and adipose tissue is known to release many inflammatory mediators. In this study, the HF intake was accompanied with significant increase in plasma *TNF-α*, but not in *IL-6* levels, whereas MitoQ only slightly attenuated this increase. However, muscle gene and protein expressions of these two cytokines were not altered by either the HF diet or MitoQ intake. It is highly likely that the source of this increased plasma *TNF-α* level is the adipose tissue, which is known to be the major sources of body cytokines.

One intriguing finding is that MitoQ intake decreased the plasma insulin level compared with both control and HF diet groups. This may suggest that MitoQ somehow increased insulin sensitivity. The decreased insulin levels could also suggest a decreased glucose-stimulated insulin release at the

Fig. 3. Muscle mitochondrial respiration in rats fed either control (cont), high-fat (HF) or HF + MitoQ diets for 8 weeks. Values are means (n 7–8 observations), and standard deviations represented by vertical bars. Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution and fresh mitochondria were isolated. (A) Mitochondria were challenged by malate + glutamate. (B) Mitochondria were challenged by malate + glutamate + succinate. (C) Mitochondria were challenged by malate + glutamate + succinate plus ADP. (D) Respiratory coefficient ratio (state 3/state 4). To detect statistical significance among groups, a one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data checked by the Kolmogorov–Smirnov test. The limit of statistical significance was set at $P < 0.05$. ^{a,b}Mean values with unlike letters for the same parameter were significantly different. † Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn's *post hoc* analysis. MitoQ, mitochondrial-targeted lipophilic ubiquinone; HF + MitoQ, HF with MitoQ.

pancreas level. However, as we did not sample the pancreas of these animals in the present study, these hypotheses will be addressed in future studies.

Because of the key role of mitochondria in lipid metabolism, obesity and IR, and because of the characteristics of MitoQ as a mitochondrial-targeted quinone, we have determined many surrogate parameters to evaluate muscle mitochondrial function and activity in this study. Both HF diet and MitoQ intake showed no notable effect on mitochondrial biogenesis as determined by CS activity and mitochondrial DNA. *Ex vivo* mitochondrial membrane potential, ROS production and activity and protein content of mitochondrial respiratory complexes, as well as mitochondrial β -oxidation activity, as measured by β -HAD and MCAD activities also remained unchanged in the three studied groups. In addition, there were no significant changes in either protein expressions or enzymatic activities of the mitochondrial respiratory chain complexes. However, the muscle mitochondrial respiration/ VO_2 was decreased with the HF diet and was re-established to the control value by MitoQ intake. The MitoQ intake restored this mitochondrial respiration probably by both modulating the fatty acid composition of mitochondrial membranes and increasing the mitochondrial quinone pool. Indeed, the later is involved as an electron and proton carrier in

mitochondrial respiration, and can act in its reduced form as an antioxidant improving mitochondrial respiration as reported by Jiménez-Santos *et al.*⁽⁴⁰⁾. This enhanced mitochondrial respiration may lead to higher fat oxidation, and thus to changes in intramuscular lipid content and composition, which may mediate the prophylactic action of MitoQ on some aspects of the metabolic syndrome. However, one limitation of *ex vivo* measurement of mitochondrial respiration is that the muscle mitochondria were not in their natural environment, and thus we should be cautious in the interpretation of these particular results.

Muscle lipid accumulation and/or lipid metabolism alteration is thought to play an important role in the development of IR in HF feeding models^(41,42). Although many reports have reported increased muscle lipid accumulation in mice/rats fed HFD, the intracellular toxic metabolites (fatty acyl CoA, DAG, ceramides and SM) are considered to be the true culprits of IR that may impair insulin signalling to glucose metabolism^(42–44). In line with this, the results of this study show that the muscle lipid profile is altered in our obesogenic diet-fed rats. The HF intake has altered different major actors of lipid metabolism and signalling – that is, (1) an increase in activities of key enzymes implicated in muscle ceramide metabolism; (2) an increase in muscle SM% and (3) a decrease in the PUFA n -3% with the HF diet. Interestingly,

Table 4. Muscle diacylglycerol (DAG) and ceramide contents and enzymes of ceramide metabolism* (Mean values and standard deviations; *n* 6–8 observations)

	Control		HF		HF + MitoQ	
	Mean	SD	Mean	SD	Mean	SD
MAG and DAG content (μg/g tissue)						
MAG†	58.9	7.6	63.6	11.2	55.8	4.9
1,2-DAG	86.6	29.3	100.0	35.7	89.8	44.5
1,3-DAG†	11.2	4.3	13.7	6.5	9.4	2.8
Total DAG	97.8	32.7	114.1	40.7	99.2	46.7
Ceramide species content (pmol/g tissue)†						
Ceramide C14	4.26a	2.81	1.21b	0.40	1.12b	0.32
Ceramide C16	2146a	635	979b	193	1006b	201
Ceramide C18	27 955	4113	28 099	5726	28 942	1606
Ceramide C18 : 1	237a	33	155b	55	156b	19
Ceramide C20	101	33	83	32	89	18
Ceramide C22	1157a	301	801b	309	867b	145
Ceramide C24	4333	1557	3455	1345	3535	767
Ceramide C24 : 1	4304a	704	2870b	1003	3074b	408
Total ceramides	40 238	5684	36 445	7813	37 700	2169
Enzymatic activity of ceramide metabolism (pmol/min per mg protein)						
Serine palmitoyltransferase	8.67	1.67	7.50	1.83	7.50	1.33
Neutral sphingomyelinase†	248a	62	323b	105	220a	43
Acidic sphingomyelinase	265	72	273	60	252	75
Neutral ceramidase	21.0a	3.3	27.8b	9.2	19.5a	6.8
Acidic ceramidase	3.17	6.00	3.83	5.50	6.50	2.50

HF, high fat; MAG, 1-monoacylglycerol.

a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at $P < 0.05$.

* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data checked by the Kolmogorov–Smirnov test.

† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn's *post hoc* analysis.

Table 5. Effects of diets on muscle phospholipid content and their class distribution* (Mean values and standard deviations; *n* 6–8 observations)

Parameters	Control		HF		HF + MitoQ	
	Mean	SD	Mean	SD	Mean	SD
Total phospholipids (μmol P/g ww)	13.7	1.2	14.5	1.3	14.4	1.1
PC (%)	54.9	1.8	53.4	2.0	55.4	1.2
PE (%)	25.1	1.3	25.8	1.7	24.8	1.5
Cardiolipin (%)	7.74	0.66	8.04	0.78	8.29	0.54
Phosphatidylinositol (%)	5.28	0.56	5.15	0.57	5.02	0.67
Phosphatidylserine (%)	2.95	0.29	2.78	0.50	2.58	0.50
SM (%)	3.96a	0.67	4.86b	0.99	3.90a	0.49
(SM/PC) × 100	7.23a	1.38	9.15b	2.13	7.05a	0.90
(PE/PC) × 100	45.8	3.8	48.4	4.7	44.8	3.6

HF, high fat; ww, wet weight; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingomyelin.

a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at $P < 0.05$.

* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data checked by the Kolmogorov–Smirnov test.

the MitoQ intake has led to the normalisation of these parameters nearly to the control values.

The HF diet intake was accompanied by a slight decrease in total ceramide content (–9.5 %) and led to a significant decrease in selective ceramide species. This may arise from diminished *de novo* ceramide synthesis (slight low SPT activity in both HF diet groups), and from its increased degradation by activation of nCDase. However, the high sphingomyelinase (SMase) activity can also balance the high nCDase activity; thus, ceramide does

not highly accumulate in skeletal muscle due to its faster turnover rate. Although MitoQ intake decreased significantly the activity of these two enzymes back to control values, this was without effect on muscle total ceramide or ceramide species contents. If some reports indicated increased muscle ceramide content after HF diet intake^(45,46), other reports failed to show such an increase⁽⁴⁷⁾. This may be due to the type of dietary lipids, the experiment duration and the muscle type⁽⁴⁵⁾.

Table 6. Effects of diets on fatty acid composition (%) of total lipids from muscle homogenate* (Mean values and standard deviations; *n* 6–8 observations)

Fatty acids	Control		HF		HF + MitoQ	
	Mean	SD	Mean	SD	Mean	SD
16:0	22.6	1.8	22.2	1.1	21.6	0.9
18:0	9.18	1.66	10.3	1.1	10.1	1.5
Total SFA	31.8	1.0	32.5	1.8	31.7	1.6
16:1 <i>n</i> -7†	2.87a	0.85	1.65b	0.55	1.57b	0.44
18:1 <i>n</i> -7†	4.31a	0.34	3.28b	0.19	3.06b	0.26
18:1 <i>n</i> -9†	9.78a	4.2	20.5b	6.9	16.1b	6.7
Total MUFA	17.8a	5.4	25.9b	7.4	21.3a,b	7.5
18:2 <i>n</i> -6	17.8	2.3	17.6	2.3	18.2	0.9
20:3 <i>n</i> -6	0.53	0.09	0.53	0.18	0.54	0.15
20:4 <i>n</i> -6†	14.6	2.5	12.4	3.5	15.7	2.1
Total <i>n</i> -6 PUFA†	34.9	3.5	30.8	5.7	33.2	5.5
18:3 <i>n</i> -3	0.50	0.18	0.47	0.14	0.48	0.21
22:5 <i>n</i> -3	1.94a	0.46	2.32a,b	0.62	2.75b	0.53
22:6 <i>n</i> -3	11.7a	2.4	7.83b	1.77	9.75a,b	2.38
Total <i>n</i> -3 PUFA	15.5a	3.7	10.8b	2.3	13.8a	2.6
Total PUFA†	50.4a	5.8	41.6b	7.8	47.0a,b	8.0

HF, high fat.

a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at $P < 0.05$.

* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data checked by the Kolmogorov–Smirnov test.

† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn's *post hoc* analysis.

Table 7. Effects of diets on fatty acid composition (%) of muscle phospholipids* (Mean values and standard deviations; *n* 6–8 observations)

Fatty acids	Control		HF		HF + MitoQ	
	Mean	SD	Mean	SD	Mean	SD
16:0	22.9	2.5	21.2	0.9	21.7	1.6
18:0	13.2	1.9	15.1	1.9	15.3	1.8
Total SFA	36.0	3.2	36.3	1.6	36.8	1.0
16:1 <i>n</i> -7†	1.34a	0.30	0.48b	0.09	0.42b	0.07
18:1 <i>n</i> -7†	4.65a	0.40	3.11b	0.19	3.10b	0.16
18:1 <i>n</i> -9†	5.04a	0.88	8.01b	2.72	5.94a	0.55
Total MUFA†	11.2a	1.3	11.8a	2.7	9.58b	0.62
18:2 <i>n</i> -6†	16.9	2.4	16.4	2.3	16.5	1.5
18:3 <i>n</i> -6	0.05	0.02	0.03	0.02	0.03	0.02
20:3 <i>n</i> -6	0.64	0.11	0.73	0.10	0.72	0.10
20:4 <i>n</i> -6	17.2a	1.3	18.0a	0.6	19.2b	1.1
Total <i>n</i> -6 PUFA	35.2	1.8	35.5	2.3	35.9	2.7
18:3 <i>n</i> -3	0.22	0.011	0.14	0.14	0.23	0.21
20:5 <i>n</i> -3	0.14	0.03	0.13	0.02	0.12	0.01
22:5 <i>n</i> -3	2.51a	0.35	3.63b	0.44	3.63b	1.05
22:6 <i>n</i> -3	14.0a	2.0	12.4b	1.0	12.5b	0.7
Total <i>n</i> -3 PUFA	18.2a	2.0	16.4b	1.3	16.8a,b	0.6
Total PUFA	53.8	2.7	51.8	1.9	53.6	1.2

HF, high fat.

a,b Mean values with unlike letters in the same row were significantly different. The limit of statistical significance was set at $P < 0.05$.

* Rats were fed their corresponding diets for 8 weeks; 16-h fasted rats were killed and muscles were sampled, rinsed with physiological solution, weighed and aliquoted and frozen for analysis. To detect statistical significance among groups, one-way ANOVA test, followed by Fischer's *post hoc* analysis, was applied for normally distributed data checked by the Kolmogorov–Smirnov test.

† Data not following normal distribution were analysed by non-parametric tests using the Kruskal–Wallis method followed by Dunn's *post hoc* analysis.

SM signalling pathway in muscle is an important factor determining the development of IR⁽⁴⁸⁾ and an important direct precursor for ceramide under the action of many different SMase⁽⁴⁹⁾. In this study, we have found that the HF intake increased muscle SM level, whereas MitoQ intake returned it to the control level. Indeed, the higher enzymatic activity of nSMase by MitoQ may be responsible for this SM decrease. SM synthase was not measurable to better determine the origin of SM increase in the HF group.

It is generally accepted that the type of dietary fat plays a far more significant role in health and disease than its absolute amount⁽⁵⁰⁾. The Western diet, characterised by excessive amounts of SFA, *n*-6 PUFA and *trans* fatty acids with decreased intake of *n*-3 PUFA, has been implicated in chronic diseases such as obesity, diabetes and CVD. In parallel, epidemiological, human and animal studies suggest that increased dietary *n*-3 PUFA may decrease the risk factors for the metabolic syndrome including central adiposity, hyperglycaemia, IR and dyslipidaemia⁽⁵¹⁾. Indeed, although the

exact mechanisms of action of *n*-3 PUFA remain unclear, many possible effects of *n*-3 PUFA on muscle metabolism related to glucose tolerance and insulin sensitivity have been proposed⁽⁵²⁾. These include potent anti-inflammatory actions mediated directly by their metabolites such as resolvins and protectins⁽⁵³⁾ and indirectly via the activation of their functional receptor GPR120 that blocks the major NF- κ B inflammation pathway⁽⁵⁴⁾. The inhibition of inflammatory cytokine production by *n*-3 PUFA decreases in turn sphingolipid synthesis, particularly ceramide and SM⁽⁵⁵⁾. Moreover, *n*-3 PUFA may induce a modification in fatty acid composition of membrane phospholipids, associated with the production of structurally different DAG that may participate in some of the protective effects of *n*-3 PUFA against various chronic diseases, including IR and diabetes type II⁽⁵⁶⁾. In line with this, Lanza *et al.*⁽⁵⁷⁾ have shown that *n*-3 PUFA protect glucose tolerance, in part by preventing the accumulation of bioactive lipid mediators that interfere with insulin action. The results of the present study show that the HF diet decreased the muscle *n*-3 PUFA content, and the intake of the mitochondria-targeted antioxidant MitoQ reestablished it to the control level. This effect may be in part responsible for the favourable effects of MitoQ on body glucose tolerance and insulin sensibility.

In conclusion, the HFD used in this study for 8 weeks was effective at inducing the major features of the metabolic syndrome in our rats – namely, moderate obesity, glucose intolerance associated with muscle mitochondrial dysfunction and marked alteration in lipid composition. Indeed, important modifications in the muscle PL classes (increase in SM and in the SM:PC ratio) in fatty acid composition of total muscle lipids and those of muscle PL (increase in MUFA, particularly C18:1 *n*-9, and decrease in PUFA, particularly PUFA *n*-3) were observed. In addition, these lipid modifications were accompanied by a significant decrease in mitochondrial respiration. All these modifications could contribute to the development of the obesity, glucose intolerance and IR observed in these rats. Interestingly, MitoQ intake corrected the lipid alterations (decreased muscle TAG, SM and C18:1 *n*-9 and increased PUFA *n*-3 levels) and restored mitochondrial respiration. Collectively, these results suggest that MitoQ protected rats exposed to a HFD from some metabolic syndrome features probably through lipid metabolism modulation and mitochondrial activity improvement. These findings suggest that MitoQ and related mitochondria-targeted ubiquinones are promising candidate compounds for future clinical studies in preventing the metabolic syndrome.

Acknowledgements

The authors thank Eva Tolika, Beatrice Bonafos, Beatrice Chabi for their appreciable technical help and Marie-Agnès Chauvin for completion of OxyBlot and OXPHOS Western blot. The authors also thank the staff of the animal facilities for animal use.

The support from the side of the EU project CM0603 is also kindly acknowledged. The authors acknowledge the financial support of the French Lipid Nutrition Group and the National (French) Institute for Agronomic Research and in particular the Human Nutrition Department (Alim-H department).

Author contributions were as follows: study design (C. F.-C. and C. C.), data collection (G. F., K. L., J. R., A. B.-Z., R. E. E., C. F., E. B., J. L.), statistical analysis (C. C. and C. F.-C.), data interpretation (C. F.-C., C. C.), manuscript preparation (C. F.-C., M. P. M., C. C.), literature search (C. F.-C. and C. C.), funds collection (C. F.-C. and C. C.). All the authors have read and approved the final version of this manuscript. M. P. M. who holds patents related to mitochondria-targeted antioxidants as therapies and serves on the scientific advisory board of Antipodean Pharmaceuticals Inc. that develops and commercialises MitoQ.

The authors declare that they have no competing interests, except M. P. M.

References

1. Johnson RJ, Stenvinkel P, Martin SL, *et al.* (2013) Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology. *Obesity (Silver Spring)* **21**, 659–664.
2. Mendoza JA, Drewnowski A & Christakis DA (2007) Dietary energy density is associated with obesity and the metabolic syndrome in U.S. adults. *Diabetes Care* **30**, 974–979.
3. Hegarty BD, Furler SM, Ye J, *et al.* (2003) The role of intramuscular lipid in insulin resistance. *Acta Physiol Scand* **178**, 373–383.
4. Boren J, Taskinen MR, Olofsson SO, *et al.* (2013) Ectopic lipid storage and insulin resistance: a harmful relationship. *J Intern Med* **274**, 25–40.
5. Koh EH, Lee WJ, Kim MS, *et al.* (2005) Intracellular fatty acid metabolism in skeletal muscle and insulin resistance. *Curr Diabetes Rev* **1**, 331–336.
6. Koves TR, Ussher JR, Noland RC, *et al.* (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. *Cell Metab* **7**, 45–56.
7. Rogge MM (2009) The role of impaired mitochondrial lipid oxidation in obesity. *Biol Res Nurs* **10**, 356–373.
8. Randle PJ, Garland PB, Hales CN, *et al.* (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet* **1**, 785–789.
9. Timmers S, Schrauwen P & de Vogel J (2008) Muscular diacylglycerol metabolism and insulin resistance. *Physiol Behav* **94**, 242–251.
10. Schrauwen P, Schrauwen-Hinderling V, Hoeks J, *et al.* (2010) Mitochondrial dysfunction and lipotoxicity. *Biochim Biophys Acta* **1801**, 266–271.
11. Hage Hassan R, Bourron O & Hajduch E (2014) Defect of insulin signal in peripheral tissues: important role of ceramide. *World J Diabetes* **5**, 244–257.
12. Montgomery MK & Turner N (2015) Mitochondrial dysfunction and insulin resistance: an update. *Endocr Connect* **4**, R1–R15.
13. Mao G, Kraus GA, Kim I, *et al.* (2010) A mitochondria-targeted vitamin E derivative decreases hepatic oxidative stress and inhibits fat deposition in mice. *J Nutr* **140**, 1425–1431.
14. Smith RA, Hartley RC & Murphy MP (2011) Mitochondria-targeted small molecule therapeutics and probes. *Antioxid Redox Signal* **15**, 3021–3038.
15. Smith RA, Hartley RC, Cocheme HM, *et al.* (2012) Mitochondrial pharmacology. *Trends Pharmacol Sci* **33**, 341–352.
16. Tauskela JS (2007) MitoQ – a mitochondria-targeted antioxidant. *IDrugs* **10**, 399–412.
17. Smith RA & Murphy MP (2011) Mitochondria-targeted antioxidants as therapies. *Discov Med* **11**, 106–114.
18. Gane EJ, Weilert F, Orr DW, *et al.* (2010) The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. *Liver Int* **30**, 1019–1026.

19. Smith RA & Murphy MP (2010) Animal and human studies with the mitochondria-targeted antioxidant MitoQ. *Ann N Y Acad Sci* **1201**, 96–103.
20. Lim S, Rashid MA, Jang M, *et al.* (2011) Mitochondria-targeted antioxidants protect pancreatic beta-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity. *Cell Physiol Biochem* **28**, 873–886.
21. Bour S, Carmona MC, Galinier A, *et al.* (2011) Coenzyme Q as an antiadipogenic factor. *Antioxid Redox Signal* **14**, 403–413.
22. Feillet-Coudray C, Fouret G, Ebabe Elle R, *et al.* (2014) The mitochondrial-targeted antioxidant MitoQ ameliorates metabolic syndrome features in obesogenic diet-fed rats better than Apocynin or Allopurinol. *Free Radic Res* **48**, 1232–1246.
23. Aoun M, Fouret G, Michel F, *et al.* (2012) Dietary fatty acids modulate liver mitochondrial cardiolipin content and its fatty acid composition in rats with non alcoholic fatty liver disease. *J Bioenerg Biomembr* **44**, 439–452.
24. Pu P, Gao DM, Mohamed S, *et al.* (2012) Naringin ameliorates metabolic syndrome by activating AMP-activated protein kinase in mice fed a high-fat diet. *Arch Biochem Biophys* **518**, 61–70.
25. Aoun M, Feillet-Coudray C, Fouret G, *et al.* (2011) Rat liver mitochondrial membrane characteristics and mitochondrial functions are more profoundly altered by dietary lipid quantity than by dietary lipid quality: effect of different nutritional lipid patterns. *Br J Nutr* **107**, 647–659.
26. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**, 248–254.
27. Baracca A, Sgarbi G, Solaini G, *et al.* (2003) Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F(0) during ATP synthesis. *Biochim Biophys Acta* **1606**, 137–146.
28. Capel F, Rimbert V, Lioger D, *et al.* (2005) Due to reverse electron transfer, mitochondrial H₂O₂ release increases with age in human *vastus lateralis* muscle although oxidative capacity is preserved. *Mech Ageing Dev* **126**, 505–511.
29. Srere P (1969) Citrate synthase. *Methods Enzymol* **13**, 3–11.
30. Teodoro JS, Rolo AP, Duarte FV, *et al.* (2008) Differential alterations in mitochondrial function induced by a choline-deficient diet: understanding fatty liver disease progression. *Mitochondrion* **8**, 367–376.
31. Djouadi F, Riveau B, Merlet-Benichou C, *et al.* (1997) Tissue-specific regulation of medium-chain acyl-CoA dehydrogenase gene by thyroid hormones in the developing rat. *Biochem J* **324**, 289–294.
32. Clayton PT, Eaton S, Aynsley-Green A, *et al.* (2001) Hyperinsulinism in short-chain α -3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. *J Clin Invest* **108**, 457–465.
33. Nulton-Persson AC & Szveda LI (2001) Modulation of mitochondrial function by hydrogen peroxide. *J Biol Chem* **276**, 23357–23361.
34. Flamment M, Rieusset J, Vidal H, *et al.* (2012) Regulation of hepatic mitochondrial metabolism in response to a high fat diet: a longitudinal study in rats. *J Physiol Biochem* **68**, 335–344.
35. Blachnio-Zabielska AU, Persson XM, Koutsari C, *et al.* (2012) A liquid chromatography/tandem mass spectrometry method for measuring the *in vivo* incorporation of plasma free fatty acids into intramyocellular ceramides in humans. *Rapid Commun Mass Spectrom* **26**, 1134–1140.
36. Blachnio-Zabielska A, Zabielski P, Baranowski M, *et al.* (2011) Aerobic training in rats increases skeletal muscle sphingomyelinase and serine palmitoyltransferase activity, while decreasing ceramidase activity. *Lipids* **46**, 229–238.
37. Bartlett GR (1959) Phosphorus assay in column chromatography. *J Biol Chem* **234**, 466–468.
38. Macala IJ, Yu RK & Ando S (1983) Analysis of brain lipids by high performance thin-layer chromatography and densitometry. *J Lipid Res* **24**, 1243–1250.
39. Fink BD, Herlein JA, Guo DF, *et al.* (2014) A mitochondrial-targeted coenzyme q analog prevents weight gain and ameliorates hepatic dysfunction in high-fat-fed mice. *J Pharmacol Exp Ther* **351**, 699–708.
40. Jiménez-Santos MA, Juárez-Rojop IE, Tovilla-Zarate CA, *et al.* (2014) Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet. *Lipids Health Dis* **13**, 22.
41. van Herpen NA & Schrauwen-Hinderling VB (2008) Lipid accumulation in non-adipose tissue and lipotoxicity. *Physiol Behav* **94**, 231–241.
42. Muoio DM (2010) Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? *Biochim Biophys Acta* **1801**, 281–288.
43. Summers SA (2006) Ceramides in insulin resistance and lipotoxicity. *Prog Lipid Res* **45**, 42–72.
44. DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. *Diabetologia* **53**, 1270–1287.
45. Blachnio-Zabielska A, Baranowski M, Zabielski P, *et al.* (2010) Effect of high fat diet enriched with unsaturated and diet rich in saturated fatty acids on sphingolipid metabolism in rat skeletal muscle. *J Cell Physiol* **225**, 786–791.
46. Bruce CR, Risis S, Babb JR, *et al.* (2012) Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice. *Diabetes* **61**, 3148–3155.
47. Jung HL & Kang HY (2010) Effects of endurance exercise and high-fat diet on insulin resistance and ceramide contents of skeletal muscle in Sprague-Dawley rats. *Korean Diabetes J* **34**, 244–252.
48. Strackowski M & Kowalska I (2008) The role of skeletal muscle sphingolipids in the development of insulin resistance. *Rev Diabet Stud* **5**, 13–24.
49. Khavandgar Z & Murshed M (2015) Sphingolipid metabolism and its role in the skeletal tissues. *Cell Mol Life Sci* **72**, 959–969.
50. Moussavi N, Gavino V & Receveur O (2008) Could the quality of dietary fat, and not just its quantity, be related to risk of obesity? *Obesity (Silver Spring)* **16**, 7–15.
51. Poudyal H, Panchal SK, Diwan V, *et al.* (2011) Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. *Prog Lipid Res* **50**, 372–387.
52. Pinel A, Morio-Liondore B & Capel F (2014) *n*-3 Polyunsaturated fatty acids modulate metabolism of insulin-sensitive tissues: implication for the prevention of type 2 diabetes. *J Physiol Biochem* **70**, 647–658.
53. Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. *Biochim Biophys Acta* **1851**, 469–484.
54. Oh DY, Talukdar S, Bae EJ, *et al.* (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell* **142**, 687–698.
55. Holland WL, Knotts TA, Chavez JA, *et al.* (2007) Lipid mediators of insulin resistance. *Nutr Rev* **65**, S39–S46.
56. Jude S, Martel E, Vincent F, *et al.* (2007) Dietary long-chain *n*-3 fatty acids modify blood and cardiac phospholipids and reduce protein kinase-C-delta and protein kinase-C-epsilon translocation. *Br J Nutr* **98**, 1143–1151.
57. Lanza IR, Blachnio-Zabielska A, Johnson ML, *et al.* (2013) Influence of fish oil on skeletal muscle mitochondrial energetics and lipid metabolites during high-fat diet. *Am J Physiol Endocrinol Metab* **304**, E1391–E1403.